J. Goldman & Co LP Takes $5.69 Million Position in Enliven Therapeutics, Inc. $ELVN

J. Goldman & Co LP bought a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, Holdings Channel.com reports. The firm bought 112,129 shares of the company’s stock, valued at approximately $5,691,000.

A number of other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in shares of Enliven Therapeutics by 70.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock valued at $26,714,000 after purchasing an additional 282,822 shares in the last quarter. Avidity Partners Management LP raised its holdings in shares of Enliven Therapeutics by 185.1% in the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock worth $15,680,000 after purchasing an additional 259,700 shares in the last quarter. Stempoint Capital LP bought a new stake in Enliven Therapeutics during the first quarter worth approximately $14,247,000. Tema ETFs LLC boosted its holdings in Enliven Therapeutics by 41.0% during the second quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after buying an additional 17,638 shares in the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in Enliven Therapeutics in the second quarter worth approximately $878,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ELVN has been the subject of several research reports. Barclays initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price objective for the company. Guggenheim decreased their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Stifel Nicolaus lifted their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. William Blair initiated coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating on the stock. Finally, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This trade represents a 64.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This trade represents a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 196,849 shares of company stock valued at $11,344,257. Corporate insiders own 3.00% of the company’s stock.

Enliven Therapeutics Trading Down 0.2%

Shares of NASDAQ ELVN opened at $61.01 on Wednesday. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The firm has a market capitalization of $4.47 billion, a PE ratio of -36.53 and a beta of 0.27. The business has a 50-day moving average price of $53.73 and a two-hundred day moving average price of $42.53.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.